Rômison Mota
Rômison Mota is the director-president of the Agência Nacional de Vigilância Sanitária (Anvisa), Brazil's health regulatory agency. He has been in the news for advocating the new regulation that will require pharmacies to retain medical prescriptions for the sale of GLP-1 receptor agonists, such as Ozempic and Wegovy, which are used for weight loss and diabetes treatment. This decision aims to curb the misuse of these medications, as many users have been obtaining them without proper medical guidance.
Not in the pool (under ¢1).
Recent news mentions
Rômison Mota was the director who proposed including a restriction on the individual importation of cannabis products.
o que muda com novas regras da Anvisa?
Brazil· 2026-01-29
Rômison Mota was the rapporteur of the measure regarding the importation of cannabis products.
Anvisa aprova novas regras; entenda o que vai mudarBrazil· 2026-01-28Rômison Mota is the director-president of Anvisa who expressed concerns about the misuse of weight loss medications.
Venda de canetas usadas para emagrecer, como Ozempic, exigirá retenção de receita, decide AnvisaBrazil· 2025-04-17
Rômison Mota is the director-president of Anvisa who discussed the need for stricter regulations on the sale of weight loss medications.
Venda de canetas usadas para emagrecer, como Ozempic, exigirá retenção de receita, decide AnvisaBrazil· 2025-04-16